Rinderpest is a highly contagious viral disease of ruminants and has greater than 95% morbidity and mortality. The etiological agent, rinderpest virus (RPV), is a member of the family Paramyxoviridae and the genus Morbillivirus. Immune responses to both the hemagglutinin (H) and the fusion (F) antigens of morbilliviruses play an important role in the prevention of infection, and only attenuated live vaccines have been shown to provide protective immunity against the group. The lack of protection with inactivated vaccines has been attributed to the denaturation of the F glycoprotein of the virus. 
Rinderpest is a highly contagious viral disease with greater than 95% morbidity and mortality in cattle and buffalo (15, 16) . The disease is characterized by high fever, profuse bloody diarrhea, and necrosis of the mucosa in the digestive tract in infected animals. It poses serious economic, social, and ecological problems in Africa, Asia, and the Middle East. Until recently, rinderpest accounted for a loss of over 2,000,000 cattle and buffalo per year (16) .
Rinderpest virus (RPV) is a member of the genus Morbillivirus of the family Paramyxoviridae; other members of the group include measles virus of humans, canine distemper virus, phocid distemper virus, and peste-des-petits-ruminants virus of goats and sheep (23) . These viruses are antigenically related and can confer cross-immunity in experimentally immunized animals (9, 16) . Like other members of the paramyxovirus group, RPV has a single-stranded RNA genome with a minus polarity. We have characterized eight proteins of the virus, including the large (L), phosphoprotein (P), hemagglutinin (H), nucleoprotein (N), fusion (F), matrix (M), and C proteins and provided evidence for another protein (V) (6, 23) . In addition, we have described the sequences of all the genes that code for these proteins, with the exception of the L protein (8, 11, 23, 24) .
There is an effective tissue culture rinderpest vaccine (TCRV) developed by Plowright that provides lifelong immunity to cattle (15) . The use of the vaccine is limited, however, because of its high cost of production, heat labil-ity, and difficulty of delivery to animals in the hot and humid regions of Africa and Asia. In contrast, the production and use of a recombinant vaccinia virus (rVV) vaccine does not require refrigeration, trained personnel, expensive tissue culture facilities, or syringes and needles for delivery.
In preparation for the development of an rVV vaccine, we propagated the highly virulent Kabete 0 strain of RPV in primary bovine kidney cells and made cDNA copies of the H (24) and F (8) genes of RPV. In addition, we constructed rVVs that expressed the F (vRVF) or the H (vRVH) or both (vRVFH) glycoproteins (5, 25) . Cattle vaccinated with either the single rVVs (vRVF or vRVH) or the double rVV (vRVFH) were completely protected when challenge inoculated with 103 50% tissue culture infective doses (TCID50) of RPV, a dose greater than 1,000 times the lethal dose of the virus. Even cattle with serum neutralization (SN) titers as low as 4 were completely protected; this substantiates previous observations that any detectable SN antibody induced by live RPV provides complete protection against the disease (9) . However, there is a concern about the safety of using rVVs, because of the report of a generalized disseminated vaccinia virus infection after smallpox vaccination of an individual positive for the human immunodeficiency virus (17) . It is, therefore, important that safety considerations be addressed before introducing live recombinant viruses into the environment, particularly in regions of Africa and Asia with a high incidence of human immunodeficiency virus.
The primary objective of this study was to assess the efficacy of the F (Fb) and H (Hb) glycoproteins of RPV expressed by recombinant baculovirus vectors Bac-F and Bac-H, respectively, as subunit vaccines for rinderpest. These inexpensively produced subunit vaccines, it was thought, might provide an alternative to rVVs in countries where safety concerns preclude the use of live recombinant vaccines.
A second objective was to determine the reasons for the failure of inactivated, whole-virus RPV vaccines to protectively immunize cattle against rinderpest. Similar observations have been made for other members of the morbillivirus group (13) . Previously, this failure was attributed to the denaturation of F glycoprotein during vaccine preparation (13) ; however, protection by vRVH alone rules out such a hypothesis (25) . In (12, 20) . Successful transfection was confirmed by the presence of polyhedrin protein (produced by the wild-type virus) within 5 days of transfection. By using serial dilutions of culture supernatant obtained from transfected Sf9 cells, a plaque assay was performed, and recombinant plaques were screened for the absence of polyhedrin protein normally found in wild-type plaques (20) . Putative polyhedrin-negative plaques were first amplified in Sf9 cells in 24-well plates, and the presence of H or F genes was identified by DNA dot blot hybridization (18, 20 mM NaCl). Samples were then dot blotted on an Immobilon-P (Millipore Co.) transfer membrane and treated for 1 h at RT in blocking solution (5% nonfat dry milk in I x TBS). The membrane was incubated with the primary antibody (1:1,000 dilution of rabbit anti-H or anti-F in blocking solution) at RT for 1 h. After being washed in lx TBS, the membrane was incubated with the second antibody (goat anti-rabbit serum conjugated to alkaline phosphatase diluted 1:2,000 in blocking solution) at RT for 1 h. Finally, the antibody-treated membrane was washed and developed by using BCIP (5-bromo-4-chloro-3-indolylphosphate) as the enzyme substrate in alkaline phosphatase buffer. (10) . After electrophoresis, proteins were transferred onto an Immobilon-P membrane in Tris-glycine buffer containing 20% methanol (20) . The membrane was probed with primary and secondary antibodies and developed in alkaline phosphatase buffer as described for the dot blot immunoassay. (5, 25) .
IMMUNE RESPONSES OF MICE AND CATTLE TO RPV PROTEINS
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Immunization studies with mice. The immunogenicity of Fb and Hb were evaluated by using CB6F1/J mice ( 
RESULTS
Construction of recombinant baculoviruses. The cloning strategies used for the generation of Bac-F and Bac-H are described in Fig. 1 Immunological characterization of recombinant H and F proteins. Recombinant glycoproteins expressed by Bac-H and Bac-F were analyzed by immunoprecipitation with Hand F-specific polyclonal antibodies (Fig. 2) . A 78-kDa H protein and a 51-kDa F protein, respectively, were identified in Bac-H-and Bac-F-infected Sf9 cells (Fig. 2) Immunization and challenge studies with cattle. The SN and ELISA titers of cattle vaccinated with Fb and Hb or a mixture of both are summarized in Table 2 and Table 3 (2,048) titers after challenge inoculation with RPV, which is indicative of viral replication and a lack of sterilizing immunity. All other animals died from severe clinical rinderpest. DISCUSSION Rinderpest, a highly contagious viral disease of cattle and buffalo, inflicts serious economic, social, and ecological damage in Africa, Asia, and the Middle East. The use of TCRV has significantly reduced the annual mortality from the disease. However, its high cost of production, heat lability, and difficulty of administration have limited the use of TCRV in the hot and arid regions of Africa and Asia (16) .
To address the economic and logistical problems associated with the use of TCRV, we developed a number of rVV vaccines for rinderpest that provided complete protection to immunized cattle when challenge inoculated with 1,000 times the lethal dose of the virus. rVVs are heat stable, easy to produce, and simple to administer. With the recent spread of the HIV epidemic in Africa and Asia, however, there are safety concerns with the use of infectious vaccinia virus. As an alternative, we have evaluated the potential use of In these studies, we used the virulent strain of RPV (Kabete 0) to obtain clones of the H and F genes (25) . The genes were then expressed under the control of the polyhedrin promoter of AcNPV. The H and F glycoproteins expressed in recombinant baculovirus-infected Sf9 cells were demonstrated by Western blot and immunoprecipitation analyses (Fig. 2 and 3) .
The (14) . The logistics of gathering and vaccinating cattle in these regions is the major reason for the failure to eradicate the disease with the heat-labile Plowright tissue culture vaccine.
Although inactivated whole virus vaccines of morbilliviruses induce SN antibodies, it has been previously demonstrated that such vaccines fail to provide protective immunity (13) . Similarly, we have demonstrated the induction of SN antibodies and the lack of protection in cattle immunized with subunit antigens expressed in baculovirus. The lack of protection with inactivated, conventional vaccines for measles virus has been attributed to denaturation of the F protein during the inactivation process (13) . We have clearly demonstrated, however, that a rVV expressing only the H protein (vRVH) provides complete protection against a challenge inoculation of 1,000 times the lethal dose of RPV (5, 25) . Complete protection against measles was demonstrated in mice vaccinated with rVVs expressing either the H or the F of measles virus glycoprotein (4). We have demonstrated that animals vaccinated with rVVs expressing either F or H antigen were completely protected even when SN titers were as low as 4 (25) . Others have succeeded, however, in inducing protective immunity in mice vaccinated with subunit preparations of H and F measles glycoprotein when presented in immune-stimulating complexes, presumably as a result of more effective presentation of these antigens to the immune system (21 
